iBio Inc. [AMEX: IBIO] stock went on an upward path that rose over 3.60% on Friday, amounting to a one-week price decrease of less than -5.26%. The company report on July 9, 2021 that iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs.
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, has taken another major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming Protein Expression System® by announcing it is adding three anti-cancer targets to its pipeline of therapeutic candidates. This development establishes the Company’s new drug discovery capabilities announced just a few weeks ago.
As part of iBio’s efforts to change the drug development paradigm with the FastPharming System by reducing the time and cost to move from initial concept to the clinic, the Company intends to partner with best-in-class technology partners to help achieve that vision. Accordingly, iBio has entered into a research services agreement with FairJourney Biologics S.A. (“FairJourney”), leaders in antibody optimization. Pursuant to the agreement, iBio will gain access to novel display technologies and proprietary antibody libraries.
Over the last 12 months, IBIO stock dropped by -36.84%. The one-year iBio Inc. stock forecast points to a potential upside of 42.4. The average equity rating for IBIO stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $302.80 million, with 215.54 million shares outstanding and 215.41 million shares in the current float. Compared to the average trading volume of 10.44M shares, IBIO stock reached a trading volume of 4683545 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on iBio Inc. [IBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBIO shares is $2.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBIO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for iBio Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 22, 2021. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on June 26, 2020, representing the official price target for iBio Inc. stock.
The Average True Range (ATR) for iBio Inc. is set at 0.09, with the Price to Sales ratio for IBIO stock in the period of the last 12 months amounting to 100.93. The Price to Book ratio for the last quarter was 2.94, with the Price to Cash per share for the same quarter was set at 0.49.
IBIO Stock Performance Analysis:
iBio Inc. [IBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.26. With this latest performance, IBIO shares dropped by -3.36% in over the last four-week period, additionally plugging by 22.03% over the last 6 months – not to mention a drop of -36.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBIO stock in for the last two-week period is set at 46.51, with the RSI for the last a single of trading hit 45.63, and the three-weeks RSI is set at 47.43 for iBio Inc. [IBIO]. The present Moving Average for the last 50 days of trading for this stock 1.4790, while it was recorded at 1.4080 for the last single week of trading, and 1.6164 for the last 200 days.
Insight into iBio Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and iBio Inc. [IBIO] shares currently have an operating margin of -854.88. iBio Inc.’s Net Margin is presently recorded at -1003.60.
Return on Total Capital for IBIO is now -23.97, given the latest momentum, and Return on Invested Capital for the company is -28.32. Return on Equity for this stock declined to -55.65, with Return on Assets sitting at -26.35. When it comes to the capital structure of this company, iBio Inc. [IBIO] has a Total Debt to Total Equity ratio set at 58.12. Additionally, IBIO Total Debt to Total Capital is recorded at 36.76, with Total Debt to Total Assets ending up at 34.94. Long-Term Debt to Equity for the company is recorded at 57.13, with the Long-Term Debt to Total Capital now at 36.13.
Reflecting on the efficiency of the workforce at the company, iBio Inc. [IBIO] managed to generate an average of -$4,109,750 per employee. Receivables Turnover for the company is 0.57 with a Total Asset Turnover recorded at a value of 0.03.iBio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.60 and a Current Ratio set at 17.70.
iBio Inc. [IBIO] Insider Position Details
There are presently around $64 million, or 20.60% of IBIO stock, in the hands of institutional investors. The top three institutional holders of IBIO stocks are: BLACKROCK INC. with ownership of 15,432,756, which is approximately 33.328% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 10,562,633 shares of the stock with an approximate value of $15.21 million in IBIO stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $4.83 million in IBIO stock with ownership of nearly 35.608% of the company’s market capitalization.
Positions in iBio Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 56 institutional holders increased their position in iBio Inc. [AMEX:IBIO] by around 14,936,776 shares. Additionally, 32 investors decreased positions by around 973,469 shares, while 21 investors held positions by with 28,433,825 shares. The mentioned changes placed institutional holdings at 44,344,070 shares, according to the latest SEC report filing. IBIO stock had 17 new institutional investments in for a total of 373,168 shares, while 16 institutional investors sold positions of 278,373 shares during the same period.